CERo Therapeutics Holdings, Inc. (CERO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CERO
- Company CERo Therapeutics Holdings, Inc.
- Price $0.43
- Changes Percentage -3.55
- Change -0.0158
- Day Low $0.4
- Day High $0.44
- Year High $102
- Year Low $0.47
- Market Cap $3,992,311
- Price Avg 50 EMA (D) $0.73
- Price Avg 200 EMA (D) $6.51
- Exchange NASDAQ
- Volume 617,104
- Average Volume 1,895,635
- Open $0.42
- Previous Close $0.45
- EPS -34.83
- PE -0.01
- Earnings Announcement 2025-04-01 04:00:00
- Shares Outstanding $7,722,072
Company brief: CERO THERAPEUTICS HOLDINGS, INC. (CERO )
- Healthcare
- Biotechnology
- Mr. Brian G. Atwood
- https://www.cero.bio
- US
- N/A
- 11-30-2021
- US71902K1051
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
CERO Corporation News
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236
globenewswire.com -- Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings,...
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
globenewswire.com -- CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evalu...